ACTIV-6 Ivermectin Study Finally Gets Going: Kudos to DCRI for Taking it On

ACTIV-6 Ivermectin Study Finally Gets Going: Kudos to DCRI for Taking it On

Duke Clinical Research Institute recently announced the elite research center is participating in the latest National Institute of Health (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), which focuses on repurposed, generic therapies targeting COVID-19. Formally titled “The Randomized Trial to Evaluate Efficacy of Repurposed Medications,” this nationwide, double-blind study is expected to enroll up to 15,000 participants across America. Therapies include Ivermectin, Fluvoxamine, and Fluticasone. But other medications are under consideration, according to TrialSite sources. Unfortunately, this kind of study comes quite late in the pandemic process, but it’s better now than never.

TrialSite has been reporting on significant investment in repurposed drugs for well over a year now. While dozens of ivermectin studies have been conducted worldwide, developed economies have been slow to embrace low-cost, effective treatments to help care for the vast segment of the COVID-19 patient market: the 90%+ of patients that are at home, either asymptomatic or with mild-to-moderate symptoms. 

At Duke, the ACTIV-6 study is led by Adrian Hernandez, MD, the ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee